G1 Therapeutics Phase 3 Trial Update: Market Response
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
- Latest
- Trending
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Arista Networks reports a revenue increase of 33.8% in 2023, reaching $5.86 billion. The company's impressive financial results and innovation ...
Shopify's Q4 earnings report is expected to showcase positive progress, with adjusted earnings per share of 30 cents, projected revenue ...
According to market capitalization rankings, U.S. companies dominate the top 20 global list, with Microsoft claiming the number one spot. ...
Arista Networks surpasses Wall Street expectations in Q4 earnings with earnings per share of $2.08 on revenue of $1.54 billion. ...
Pandora faces competition from Ethereum token standard DN404, which aims to offer a more efficient solution. Pandora's recovery and surge ...
Jeff Bezos aims to reclaim the title of the world's richest person from Elon Musk by selling up to 50 ...
Shares of Microsoft Corp. dropped 1.26% in a mixed trading session, ending a three-day winning streak. The stock underperformed compared ...
The Hennessy Cornerstone Mid Cap 30 Fund's simple investing strategy consistently outperforms complex tactics used by Wall Street. The fund's ...
Cadence Design Systems reports strong Q4 results, surpassing analyst estimates for earnings per share and revenue. The company's stock has ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.